Purple Biotech shares are trading lower by 28% during Tuesday's session. The company announced a $2.8 million offering. Purple Biotech's Phase 2 trial of CM24 in metastatic PDAC patients showed ...

Accordingly, the stock price of the company’s shares decreases ... ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets.